Quetiapine as a first-choice agent in subjects at high-risk to psychosis?

Medical Hypotheses

Volumn 69, Issue 1, 2007, Pages 230-

  O'Connor, Ryan ^a   Sota, Malinda ^b   Cortesi, Mariachiara ^b   Fusar Poli, Paolo ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE;

CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INTERVENTION STUDY; LETTER; MENTAL HEALTH; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 34248143546     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.11.037     Document Type: Letter

References (7)

1. Miller T.J., McGlashan T.H., Rosen J.L., et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiat 159 5 (2002) 863-865
2. Yung A.R., Phillips L.J., Yuen H.P., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 60 1 (2003) 21-32
3. Yung A.R., Stanford C., Cosgrave E., Killackey E., Phillips L., Nelson B., et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 84 1 (2006) 57-66 [Epub 2006 Apr 21]
4. Kopala L.C., Good K.P., Milliken H., Buiteman C., Woodley H., Rui Q., et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res 81 1 (2006) 29-39 [Epub 2005 Nov 2]
5. Allison D., Mentore J., Heo M., et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiat 156 (1999) 1686-1696
6. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiat 63 (2002) 425-433
7. Seidman L.J., Giuliano A.J., Smith C.W., Stone W.S., Glatt S.J., Meyer E., et al. Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull 32 3 (2006) 507-524 [Epub 2006 May 17]